Brown, Lisle/Cummings, Inc. Arbutus Biopharma Corp Put Options Transaction History
Brown, Lisle/Cummings, Inc.
- $307 Billion
- Q2 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding ABUS
# of Institutions
129Shares Held
82.1MCall Options Held
4.82MPut Options Held
546K-
Whitefort Capital Management, LP New York, NY12.9MShares$50.2 Million24.48% of portfolio
-
Black Rock Inc. New York, NY10.4MShares$40.6 Million0.0% of portfolio
-
Morgan Stanley New York, NY8.83MShares$34.4 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY7.84MShares$30.6 Million10.39% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.99MShares$23.4 Million0.0% of portfolio
About Arbutus Biopharma Corp
- Ticker ABUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 149,951,008
- Market Cap $585M
- Description
- Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...